498 related articles for article (PubMed ID: 8701600)
1. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections.
De Clercq E
Verh K Acad Geneeskd Belg; 1996; 58(1):19-47; discussion 47-9. PubMed ID: 8701600
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
Snoeck R; Andrei G; Gérard M; Silverman A; Hedderman A; Balzarini J; Sadzot-Delvaux C; Tricot G; Clumeck N; De Clercq E
Clin Infect Dis; 1994 Apr; 18(4):570-8. PubMed ID: 8038312
[TBL] [Abstract][Full Text] [Related]
3. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates.
Aduma P; Connelly MC; Srinivas RV; Fridland A
Mol Pharmacol; 1995 Apr; 47(4):816-22. PubMed ID: 7723743
[TBL] [Abstract][Full Text] [Related]
4. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections.
De Clercq E
Intervirology; 1997; 40(5-6):295-303. PubMed ID: 9675635
[TBL] [Abstract][Full Text] [Related]
5. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
Neyts J; De Clercq E
Verh K Acad Geneeskd Belg; 1994; 56(6):561-92. PubMed ID: 7892749
[TBL] [Abstract][Full Text] [Related]
6. HPMPC, a broad-spectrum topical antiviral agent, inhibits herpes simplex virus type 1 replication and promotes healing of dendritic keratitis in the New Zealand rabbit ocular model.
Gordon YJ; Romanowski EG; Araullo-Cruz T
Cornea; 1994 Nov; 13(6):516-20. PubMed ID: 7842711
[TBL] [Abstract][Full Text] [Related]
7. A review of topical and intralesional cidofovir.
Zabawski EJ
Dermatol Online J; 2000 Sep; 6(1):3. PubMed ID: 11328613
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG).
Neyts J; Snoeck R; Schols D; Balzarini J; De Clercq E
Virology; 1990 Nov; 179(1):41-50. PubMed ID: 2171213
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy of the acquired immune deficiency syndrome (AIDS): acyclic nucleoside phosphonate analogues.
De Clercq E
Int J Immunopharmacol; 1991; 13 Suppl 1():91-8. PubMed ID: 1823910
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of phosphonylmethoxyalkylpurines and -pyrimidines as antiviral agents.
De Clercq E
Drugs Exp Clin Res; 1990; 16(7):319-26. PubMed ID: 1965499
[TBL] [Abstract][Full Text] [Related]
11. Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections.
De Clercq E
Expert Rev Anti Infect Ther; 2003 Jun; 1(1):21-43. PubMed ID: 15482100
[TBL] [Abstract][Full Text] [Related]
12. Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients.
Snoeck R; De Clercq E
Curr Opin Investig Drugs; 2002 Nov; 3(11):1561-6. PubMed ID: 12476953
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice.
De Clercq E; Holý A
Antimicrob Agents Chemother; 1991 Apr; 35(4):701-6. PubMed ID: 2069375
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine.
Johnson JA; Gangemi JD
Antimicrob Agents Chemother; 1999 May; 43(5):1198-205. PubMed ID: 10223936
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines.
Andrei G; Snoeck R; Piette J; Delvenne P; De Clercq E
Oncol Res; 1998; 10(10):523-31. PubMed ID: 10338155
[TBL] [Abstract][Full Text] [Related]
16. Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention.
Chavez-de la Paz E; Arevalo JF; Kirsch LS; Munguia D; Rahhal FM; De Clercq E; Freeman WR
Ophthalmology; 1997 Mar; 104(3):539-44. PubMed ID: 9082286
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of acyclic nucleoside phosphonates against herpes virus replication.
Neyts J; De Clercq E
Biochem Pharmacol; 1994 Jan; 47(1):39-41. PubMed ID: 8311844
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs.
Bravo FJ; Stanberry LR; Kier AB; Vogt PE; Kern ER
Antiviral Res; 1993 May; 21(1):59-72. PubMed ID: 8391249
[TBL] [Abstract][Full Text] [Related]
19. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model.
Romanowski EG; Bartels SP; Gordon YJ
Invest Ophthalmol Vis Sci; 1999 Feb; 40(2):378-84. PubMed ID: 9950596
[TBL] [Abstract][Full Text] [Related]
20. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.
De Clercq E
Clin Microbiol Rev; 2003 Oct; 16(4):569-96. PubMed ID: 14557287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
